ArticleClinical science (London, England : 1979)2025
Lauryl gallate promotes platelet activation and thrombus formation: a promising application to stop bleeding.
Article in Clinical science (London, England : 1979), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lauryl gallate (LG, E312) is an antioxidant with hydrophobic properties that contribute to its activity by increasing affinity for membranes and acting on the lipid phase transition and likely the lateral membrane organization. Here, we show that LG at a low concentration has the ability to spontaneously induce washed human platelet shape change, filopodia emission, granule secretion, and aggregation. LG was able to activate intracellular signaling pathways, including Akt, p38MAP kinase, inositol phosphate, and calcium responses, as well as to trigger cyclic adenosine monophosphate decrease and αIIbβ3 integrin activation. LG significantly potentiated platelet aggregation induced by low concentrations of agonists, and the addition of low doses of LG to human blood strongly increased the platelet thrombotic response under arterial flow on a collagen matrix. Morphological analysis by scanning electron microscopy indicated that contrary to low doses, high concentrations of LG induced dramatic platelet membrane modifications associated with calcium influx, lactate dehydrogenase leakage, and a slow platelet aggregation response. Interestingly, a local flash application of LG efficiently decreased the tail bleeding time in rats. LG action was rapid and significantly more efficient than tranexamic acid, an antifibrinolytic agent, pointing to its hemostatic potential. Overall, our results indicate that LG, likely through its capacity to modify membrane lateral organization, has important pro-aggregant and antihemorrhagic properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.